Heidelberg Pharma AG (HPHA.DE)
EUR 2.38
(-0.42%)
EUR 2.38
(-0.42%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -18.7 Million EUR | -64.4% |
| 2022 | -16.18 Million EUR | 34.77% |
| 2021 | -24.82 Million EUR | -40.9% |
| 2020 | -17.55 Million EUR | -79.58% |
| 2019 | -9.59 Million EUR | 13.14% |
| 2018 | -11.71 Million EUR | -9.25% |
| 2017 | -10.34 Million EUR | -70.16% |
| 2016 | -6.07 Million EUR | 2.78% |
| 2015 | -6.2 Million EUR | -25.06% |
| 2014 | -5.08 Million EUR | 29.05% |
| 2013 | -3.16 Million EUR | 14.45% |
| 2012 | -8.2 Million EUR | 35.9% |
| 2011 | -12.85 Million EUR | 43.8% |
| 2010 | -22.87 Million EUR | -83.42% |
| 2009 | -12.46 Million EUR | 38.18% |
| 2008 | -20.16 Million EUR | -222.32% |
| 2007 | -21.95 Million EUR | 51.86% |
| 2006 | -17.51 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -4.85 Million EUR | 7.68% |
| 2024 Q2 | -5.57 Million EUR | 3.88% |
| 2024 Q3 | -5.37 Million EUR | -35.57% |
| 2023 Q2 | -8.87 Million EUR | -48.86% |
| 2023 Q1 | -5.95 Million EUR | 1.17% |
| 2023 Q3 | 592.45 Thousand EUR | 106.68% |
| 2023 Q4 | -4.35 Million EUR | -834.69% |
| 2023 FY | - EUR | -64.4% |
| 2022 Q4 | -6.02 Million EUR | -43.45% |
| 2022 Q1 | -6.88 Million EUR | 0.24% |
| 2022 Q2 | 926.55 Thousand EUR | 113.46% |
| 2022 Q3 | -4.2 Million EUR | -553.64% |
| 2022 FY | - EUR | 34.77% |
| 2021 Q1 | -6.09 Million EUR | -9.64% |
| 2021 Q3 | -5.4 Million EUR | 16.04% |
| 2021 Q4 | -6.89 Million EUR | -27.61% |
| 2021 Q2 | -6.43 Million EUR | -5.66% |
| 2021 FY | - EUR | -40.9% |
| 2020 Q1 | -4.44 Million EUR | 1.95% |
| 2020 FY | - EUR | -79.58% |
| 2020 Q2 | -4.71 Million EUR | -6.09% |
| 2020 Q3 | -2.9 Million EUR | 38.35% |
| 2020 Q4 | -5.55 Million EUR | -91.3% |
| 2019 FY | - EUR | 13.14% |
| 2019 Q1 | -2.97 Million EUR | 28.58% |
| 2019 Q2 | -1.13 Million EUR | 61.99% |
| 2019 Q3 | -1.18 Million EUR | -4.44% |
| 2019 Q4 | -4.53 Million EUR | -283.71% |
| 2018 Q1 | -2.33 Million EUR | 27.49% |
| 2018 Q2 | -2.19 Million EUR | 6.08% |
| 2018 FY | - EUR | -9.25% |
| 2018 Q4 | -4.16 Million EUR | -59.91% |
| 2018 Q3 | -2.6 Million EUR | -18.63% |
| 2017 FY | - EUR | -70.16% |
| 2017 Q3 | -3.22 Million EUR | -40.98% |
| 2017 Q4 | -3.22 Million EUR | 0.12% |
| 2017 Q2 | -2.28 Million EUR | -32.84% |
| 2017 Q1 | -1.72 Million EUR | 22.37% |
| 2016 Q2 | -1.71 Million EUR | -58.22% |
| 2016 Q3 | -1.64 Million EUR | 4.29% |
| 2016 FY | - EUR | 2.78% |
| 2016 Q1 | -1.08 Million EUR | 62.59% |
| 2016 Q4 | -2.22 Million EUR | -35.08% |
| 2015 Q2 | -1.26 Million EUR | -26.94% |
| 2015 FY | - EUR | -25.06% |
| 2015 Q1 | -999.14 Thousand EUR | 72.7% |
| 2015 Q4 | -2.9 Million EUR | -68.04% |
| 2015 Q3 | -1.72 Million EUR | -36.15% |
| 2014 FY | - EUR | 29.05% |
| 2014 Q4 | -3.65 Million EUR | -3025.31% |
| 2014 Q3 | -117.1 Thousand EUR | 92.02% |
| 2014 Q2 | -1.46 Million EUR | 46.46% |
| 2014 Q1 | -2.74 Million EUR | -1321.24% |
| 2013 Q4 | 224.41 Thousand EUR | 144.12% |
| 2013 FY | - EUR | 14.45% |
| 2013 Q1 | -1.78 Million EUR | -1.72% |
| 2013 Q2 | -1.87 Million EUR | -4.63% |
| 2013 Q3 | -508.7 Thousand EUR | 72.83% |
| 2012 FY | - EUR | 35.9% |
| 2012 Q1 | -2.19 Million EUR | -539.42% |
| 2012 Q2 | -3.57 Million EUR | -63.33% |
| 2012 Q3 | -1.95 Million EUR | 45.49% |
| 2012 Q4 | -1.75 Million EUR | 9.79% |
| 2011 Q1 | -5.84 Million EUR | -0.49% |
| 2011 Q3 | -2.29 Million EUR | 47.57% |
| 2011 Q2 | -4.37 Million EUR | 25.13% |
| 2011 FY | - EUR | 43.8% |
| 2011 Q4 | -342.65 Thousand EUR | 85.06% |
| 2010 FY | - EUR | -83.42% |
| 2010 Q2 | -6.1 Million EUR | -14.27% |
| 2010 Q3 | -5.61 Million EUR | 8.0% |
| 2010 Q1 | -5.33 Million EUR | -233.91% |
| 2010 Q4 | -5.81 Million EUR | -3.55% |
| 2009 Q4 | -1.59 Million EUR | -185.56% |
| 2009 Q3 | -560.02 Thousand EUR | 87.94% |
| 2009 Q2 | -4.64 Million EUR | 17.94% |
| 2009 Q1 | -5.66 Million EUR | 0.0% |
| 2009 FY | - EUR | 38.18% |
| 2008 FY | - EUR | -222.32% |
| 2007 FY | - EUR | 51.86% |
| 2006 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| BioNTech SE | 1.08 Billion EUR | 101.72% |
| CureVac N.V. | -234.09 Million EUR | 92.009% |
| Biotest Aktiengesellschaft | 179 Million EUR | 110.45% |
| Biotest Aktiengesellschaft | 179 Million EUR | 110.45% |
| BRAIN Biotech AG | -2.38 Million EUR | -683.677% |
| Formycon AG | 81.05 Million EUR | 123.079% |
| Medigene AG | -14.58 Million EUR | -28.258% |